Methylene Blue for Treatment of Hospitalized COVID-19 Patients, Randomized, Controlled, Open-Label Clinical Trial, Phase 3

Daryoush Hamidi Alamdari* (Corresponding Author), Saied Hafizi Lotfabadi, Behzad Mavaji Darban, Marzieh Agheli-Rad, Shahin Saadatian, Seyed Hadi Hashemi, Fatemeh Barazandeh Ahmadabadi, Negar Morovatdar, Mohammad Arastoo, bharat Bhushan

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Downloads (Pure)

Abstract

Background: Methylene blue (MB) possesses all the required properties for the clinical management of COVID-19. We have coined methylene blue as an anti-hypoxemia and anti-respiratory distress agent and previously witnessed promising results in phase 1 & 2 clinical trials. Methods: In the phase 3 clinical trial, the efficacy of MB has been evaluated as an adjunct therapy along with standard care protocols in the treatment of COVID-19 patients. A randomized, controlled, open-label clinical trial was conducted from 20 September through to 20 November 2020, and two hundred twenty-three hospitalized patients with confirmed severe cases of COVID-19 were recruited. Patients were randomly assigned to receive either oral MB (the reduced form: 1mg/kg T.I.D. for 2- days, followed by 1mg/kg B.I.D. for the next 12 days) along with standard care (MBgroup: 106) or standard care alone (SC-group: 117). The outcomes were duration of hospital stay and mortality. Results: The hospital stay, measured in days, was significantly shortened in the MBgroup (6.2 ± 3.1) in comparison to the SC-group (10.6 ± 9.2, p<0.001), and a marginal significant decrease in mortality was seen in the MB-group (12.2%) in comparison to SC-group (21.4%, p= 0.07). Conclusions: We conclude that MB, as an adjunct therapy, can be used along with standard care protocols for the treatment of COVID-19. Larger studies in other centers are needed to confirm these findings. MB is a low-cost and FDA-approved drug for methemoglobinemia.
Original languageEnglish
Article number2
Pages (from-to)12-18
Number of pages7
JournalAristotle Biomedical Journal
Volume3
Issue number2
Publication statusPublished - 2021

Keywords

  • COVID-19
  • Treatment
  • Methylene Blue
  • Mortality

Fingerprint

Dive into the research topics of 'Methylene Blue for Treatment of Hospitalized COVID-19 Patients, Randomized, Controlled, Open-Label Clinical Trial, Phase 3'. Together they form a unique fingerprint.

Cite this